Palisade Bio

Yahoo Finance • 7 days ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) 

Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio’s Phase... Full story

Yahoo Finance • 17 days ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-21... Full story

Yahoo Finance • 29 days ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patie... Full story

Yahoo Finance • last year

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anti... Full story

Yahoo Finance • last year

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio(Nasdaq: PALI), a biopharmaceutical company focused on... Full story

Yahoo Finance • last year

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of IND-enabling studies with IND filing expected by Q3 2024 –Inflammatory bowel disease (IBD) represents a multi-billion dollar... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complication... Full story

Yahoo Finance • 2 years ago

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) co... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11,... Full story

Yahoo Finance • 2 years ago

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canad... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and ch... Full story

Yahoo Finance • 2 years ago

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 Carlsbad, CA, March 23, 2023 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 2 years ago

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has... Full story

Yahoo Finance • 2 years ago

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Topline data readout from study expected in first half of 2023 Carlsbad, CA, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastr... Full story

Yahoo Finance • 2 years ago

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

Established academic and corporate executive with proven track record leading large, multinationalorganizations across the pharmaceutical and medical device industries Well-versed with LB1148 -serving as recent expert clinical advisor to... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces Reverse Stock Split

Carlsbad, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced a 1-for-50 revers... Full story

Yahoo Finance • 2 years ago

Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company” or “Palisade”), re... Full story

Yahoo Finance • 2 years ago

Palisade Bio Announces Executive Leadership Transition

Board Appoints JD Finley to Interim Chief Executive Officer Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastroin... Full story